Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

When B cells rebuff bispecifics

Adam J. Olszewski

Blood (2024) 143 (9): 744–746.

https://doi.org/10.1182/blood.2023023312

Published: 2024

Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Blood (2023) 142 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2023-180333

Published: 2023

Journal Articles

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Narendranath Epperla, Natalie S. Grover, Kaitlin Annunzio, Marcus P Watkins, Pallawi Torka, Reem Karmali, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey P. Shouse, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 266.

https://doi.org/10.1182/blood-2023-185152

Published: 2023

Journal Articles

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Narendranath Epperla, Kaitlin Annunzio, Geoffrey P. Shouse, Natalie S. Grover, Pallawi Torka, Marcus P Watkins, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2023-185205

Published: 2023

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL)

Habib Hamidi, Patrick Kimes, Aaron Schroeder, Jasmina Uzunovic, Adam J Olszewski, Jason Sit, Enkhtsetseg Purev, Donald Yee, Ron McCord

Blood (2023) 142 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2023-177591

Published: 2023

Journal Articles

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Adam J Olszewski, Thomas Ollila, Ari Pelcovits, Anna Dorota Chorzalska, John Morgan, Jessica McMahon, Stephen Donnelly, Scott F. Huntington, Matthew Matasar, John L. Reagan, Charles Milrod, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2023-181418

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Blood (2023) 142 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2023-185182

Published: 2023

Journal Articles

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Charles Milrod, Kang Woo Kim, Thomas Ollila, Adam J Olszewski, Ari Pelcovits

Blood (2023) 142 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2023-177626

Published: 2023

Journal Articles

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Pamela Egan, Ari Pelcovits, Caitlyn Krar, Stephen Donnelly, Lila Rubin, Rabin Niroula, John L. Reagan, Dana Guyer, Adam J Olszewski, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 259.

https://doi.org/10.1182/blood-2023-187645

Published: 2023

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

Sry-Box Transcription Factor 9 (SOX9)-Driven Mesenchymal Stromal Cell Differentiation Signature As a Determinant of Induction Chemotherapy Responsiveness in Acute Myeloid Leukemia Core Bone Marrow Biopsies

Seo-Ho Lee, Dennis M Bonal, Diana Olguta Treaba, Anna Dorota Chorzalska, Makayla Pardo, John L. Reagan, Adam J Olszewski, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2023-189679

Published: 2023

Journal Articles

Loss of Complement Factor I (Cfi) a Negative Regulator of Complement Cascade Activity Exacerbates JAK2V617F-Dependent Phenotype

Alissa Oakes, Dennis M Bonal, Zoe Creane, Hyunju Oh, Anna Dorota Chorzalska, Brooke Sadler, John L. Reagan, Rabin Niroula, Adam J Olszewski, Gabriel Haller, Stephen Donnelly, Patrycja M Dubielecka

Blood (2023) 142 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2023-189483

Published: 2023

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Meet the Burkitts: a dark zone family

Adam J. Olszewski

Blood (2023) 141 (8): 816–818.

https://doi.org/10.1182/blood.2022018509

Published: 2023

Journal Articles

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Kaitlin Annunzio, Natalie S. Grover, Rui Li, Daniel Jones, Walter Hanel, Beth Christian, Adam J. Olszewski, Narendranath Epperla

Blood (2022) 140 (Supplement 1): 3644–3645.

https://doi.org/10.1182/blood-2022-164892

Published: 2022

Journal Articles

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Adam J. Olszewski, Scott F. Huntington, Rajat Bannerji, Thomas A. Ollila, Jessica McMahon, Patrycja M Dubielecka

Blood (2022) 140 (Supplement 1): 6492–6493.

https://doi.org/10.1182/blood-2022-157463

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, Matthew McKinney, Dariusz Woszczyk, Krzysztof Giannopoulos, Wojciech Jurczak, Diana Dunshee, Annie Yang, Mingzhu Zhou, Naseer Qayum, Gila Sellam, Netanel A. Horowitz

Blood (2022) 140 (Supplement 1): 1778–1780.

https://doi.org/10.1182/blood-2022-157768

Published: 2022

Journal Articles

Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study

Narendranath Epperla, Rui Li, Pallawi Torka, Lauren Shea, Reem Karmali, Andrea Anampa-Guzman, Timothy Seijung Oh, Kathryn Lindsey, Irl Brian Greenwell, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Geoffrey Shouse, Alex F. Herrera, Nancy L. Bartlett, Natalie S. Grover, Adam J. Olszewski

Blood (2022) 140 (Supplement 1): 1926–1928.

https://doi.org/10.1182/blood-2022-166785

Published: 2022

NARROW

When B cells rebuff bispecifics

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL)

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Sry-Box Transcription Factor 9 (SOX9)-Driven Mesenchymal Stromal Cell Differentiation Signature As a Determinant of Induction Chemotherapy Responsiveness in Acute Myeloid Leukemia Core Bone Marrow Biopsies

Loss of Complement Factor I (Cfi) a Negative Regulator of Complement Cascade Activity Exacerbates JAK2V617F-Dependent Phenotype

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Meet the Burkitts: a dark zone family

Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only